Dr Reddy's Laboratories lost 3.74% to Rs 4,083 at 14:38 IST on BSE after the company recalled one batch of USP 1.5 mg Rivastigmine Tartarate capsule from the US market.
Meanwhile, the S&P BSE Sensex was down 1,426.55 points or 5.21% at 25,939.52
On BSE, so far 10,105 shares were traded in the counter as against average daily volume of 18,583 shares in the past one quarter.
The stock hit high of Rs 4,199.95 and a low of Rs 4,044.65 so far during the day. The stock had hit a record high of Rs 4,337 on 14 August 2015. The stock had hit a 52-week low of Rs 2,794.85 on 22 August 2014.
The stock had outperformed the market over the past one month till 21 August 2015, rising 10.11% compared with 2.9% fall in the Sensex. The stock also outperformed the market in past one quarter, gaining 17.15% as against Sensex's 1.59% decline.
The large-cap pharma firm has equity capital of Rs 85.28 crore. Face value per share is Rs 5.
The stock fell even as Dr Reddy's Laboratories clarified after market hours on Friday, 21 August 2015, that the voluntary recall of one batch of USP 1.5 mg Rivastigmine Tartarate capsule from the US market is a batch-specific voluntary recall in conformance with the company's quality assurance norms and that the business impact from this recall will not be substantial.
On consolidated basis, Dr Reddy's Laboratories' net profit rose 13.7% to Rs 625.65 crore on 6.8% growth in net sales to Rs 3757.76 crore in Q1 June 2015 over Q1 June 2014.
Dr Reddy's Laboratories is an integrated global pharmaceutical company. Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products - Dr Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations.
Powered by Capital Market - Live News
